Litigation Details for Abbott Diabetes Care Inc. v. Dexcom, Inc. (D. Del. 2021)

Abbott Diabetes Care Inc. v. Dexcom, Inc. (D. Del. 2021)

Docket		Date Filed	2021-07-01
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Kent A. Jordan
Jury Demand	Plaintiff	Referred To
Patents	6,217,866; 9,056,057
Link to Docket	External link to docket

Details for Abbott Diabetes Care Inc. v. Dexcom, Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-03-22	307	Opinion - Memorandum Opinion	would be familiar with. (D.I. 108, Exhibit Eat 9:56--57; D.I. 136 at ,r 160.) The specification also describes…'341 patent, 7 and 23 of the '654 patent, and 2 and 29 of the '216 patent include limitations…of twelve United States Patents Nos. 10,820,842 ("the '842 patent"), 10,827,954 ("…quot;the '954 patent"), 10,874,338 ("the '338 patent"), 10,881,341 ("the…the '341 patent"), 10,945,647 ("the '647 patent"), 10,945,649 ("the '	External link to document
2023-10-04	529	Jury Instructions - Proposed	binding of EGF to the EGF receptor.” U.S. Patent 6,217,866. They now take the position that Figure 1(…the 338 patent, claim 3 of the 647 patent, claim 29 of the 649 patent, claim 10 of the 654 patent, claims…refer to each patent by the last three numbers of its patent number. For example, U.S. Patent No. 10,874,338…and 18 of the 443 patent, claim 2 of the 216 patent, and claim 24 of the 440 patent. These specific claims…(collectively, “the Asserted Patents”). A copy of each of these patents will be given to you. For your	External link to document